Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of tofacitinib versus etanercept and placebo in moderate to severe chronic plaque psoriasis
2010-020004-30Phase 3Completed
- Sponsor
- Pfizer
- Start
- Aug 2010
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of tofacitinib and etanercept in psoriasis (4 arms), sponsored by Pfizer. Primary endpoints: Reduction in severity of plaque psoriasis after 12 weeks of treatment and Reduction in pruritus during 12 weeks of treatment. Started Aug 2010; status: completed.
02
Drugs
tofacitinibetanercept
03
Conditions
psoriasis
Beyond the preview
Go deeper on 2010-020004-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-020004-30.